Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| XBiotech Inc.XBIT · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required |
| Reliability | 0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| Peer failure rate | 1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $120M to $591M assetstotal assets $150.1M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | thin data, degenerate inputsnot computable: distress, fortress balance sheet |
| Inputs computable | 5 of 14 |
| Graded from | filings received through Apr 29, 2026163 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $2.182026-10-08; market equity $66.5M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 13, 2026; the document on sec.gov.
XBiotech Inc. (“XBiotech” or the “Company”) is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. XBiotech was incorporated in Canada on March 22, 2005. The Company’s Internet address is www.xbiotech.com.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 70.2 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31 | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (3.2%) | [1,3-5] | (6.6%) | 70.2 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 4 | |||||||
| Solvency, sleeve percentile 5.2 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | 14.89 | [1,6-11] | (0.31) | 4.6 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| one or more required annual facts are missing | |||||||
| Current ratio | 16.01x | [6-7] | 2.96x | 5.7 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 44.5 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| current value must be positive and the base must exceed $100,000 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| pretax income must exceed the validity floor and imply a 0%-100% tax rate | |||||||
| Asset growth, three years | (15.2%) | [1,5,12-13] | 2.1% | 76.5 | 704 | 2025-12-31 | |
| Net share issuance, one year | 0.0% | [14-15] | 2.5% | 12.4 | 634 | 2026-03-13 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (13.5%) | 8.0% | 36 | hotter than 36 of 100 peers |
| Distance from 52-week high | (25.2%) | (31.4%) | 58 | closer to its high than 58 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | (59.9%) | (1.0%) | 10 | pricier than 90 of 100 peers |
| Book value to price | 1.92 | 0.28 | 96 | pricier than 4 of 100 peers |
| Sales to price | 0.00 | 0.31 | 0 | pricier than 100 of 100 peers |
| Composite equity issuance, five years | (11.5%) | 20.3% | 14 | more equity-funded than 14 of 100 peers |
| Relative strength against the sector, log excess return | (0.36) | (0.14) | 36 | ahead of 36 of 100 peers |
Inputs: market equity $67.1M; EBIT -$55.7M; free cash flow -$40.2M; book equity $128.5M; sales $0; cash $109.5M[16].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (22.9%) | ✗ fail[3,5] |
| Operating cash flow above zero | -$39.9M | ✗ fail[4] |
| Return on assets improved | (5.9 pts) | ✗ fail[3,5,12,17] |
| Operating cash flow exceeds net income | $5.6M | ✓ pass[3-4] |
| Long-term leverage fell | n/a[1,5,12] | |
| Current ratio improved | 445.4 pts | ✓ pass[6-7,18-19] |
| No new shares issued | 0.0% | ✓ pass[14-15] |
| Gross margin improved | n/a | |
| Asset turnover improved | n/a[5,12] | |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $109.5M[20] |
| Operating cash flow, four quarters | -$40.7M[4,20-24] |
| Months of runway | 32.3 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 57 |
| 10-Q received Aug 13, 2026 | |
| Median daily dollar volume | $64,181 |
| 63 sessions | |
| Days since newest grade input | 163 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $150.1M | 2025-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax | $0 | 2023-12-31 | 2024-03-15 | 10-K | filing · viewer · series |
| 3 | net income | us-gaap:NetIncomeLoss | -$45.5M | 2025-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$39.9M | 2025-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 5 | assets | us-gaap:Assets | $199.1M | 2024-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 6 | current assets | us-gaap:AssetsCurrent | $127.0M | 2025-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 7 | current liabilities | us-gaap:LiabilitiesCurrent | $7.9M | 2025-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 8 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$136.4M | 2025-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 9 | operating income | us-gaap:OperatingIncomeLoss | -$55.7M | 2025-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 10 | book equity | us-gaap:StockholdersEquity | $140.3M | 2025-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 11 | liabilities | us-gaap:Liabilities | $9.7M | 2025-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 12 | assets | us-gaap:Assets | $226.6M | 2023-12-31 | 2025-03-18 | 10-K | filing · viewer · series |
| 13 | assets | us-gaap:Assets | $246.1M | 2022-12-31 | 2024-03-15 | 10-K | filing · viewer · series |
| 14 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 30,487,731 | 2026-03-13 | 2026-04-29 | 10-K/A | filing · viewer · series |
| 15 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 30,487,731 | 2025-03-18 | 2025-04-29 | 10-K/A | filing · viewer · series |
| 16 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 30,487,731 | 2026-08-13 | 2026-08-13 | 10-Q | filing · viewer · series |
| 17 | net income | us-gaap:NetIncomeLoss | -$38.5M | 2024-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 18 | current assets | us-gaap:AssetsCurrent | $174.6M | 2024-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 19 | current liabilities | us-gaap:LiabilitiesCurrent | $15.1M | 2024-12-31 | 2026-03-13 | 10-K | filing · viewer · series |
| 20 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $109.5M | 2026-06-30 | 2026-08-13 | 10-Q | filing · viewer · series |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$13.5M | 2026-06-30 | 2026-08-13 | 10-Q | filing · viewer · series |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$9.0M | 2026-03-31 | 2026-05-14 | 10-Q | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$17.0M | 2025-09-30 | 2025-11-12 | 10-Q | filing · viewer · series |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$12.7M | 2025-06-30 | 2026-08-13 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.